Illumina, Bristol-Myers Squibb partner to develop NGS-based companion diagnostics in oncology

Bristol-Myers Squibb and Illumina announced Friday a collaboration that will develop and market a companion diagnostic (CDx) version of Illumina's next-generation sequencing (NGS) test TruSight Oncology 500 assay to measure potentially predictive genomic biomarkers in support of Bristol-Myers Squibb's oncology portfolio.

Garret Hampton, Illumina's executive vice president of clinical genomics, remarked that NGS assays, such as a CDx version of TruSight Oncology 500, "are ideally suited to the comprehensive interrogation of a patient's cancer." He added that we see "tremendous promise in this partnership" with Bristol-Myers Squibb "to co-develop next-generation sequencing-based diagnostics that can identify effective therapeutic combinations and provide global access to these targeted drugs." Meanwhile, Saurabh Saha, Bristol-Myers Squibb's global head of translational medicine, noted that "we are excited to partner with Illumina to pursue development of diagnostics that can help predict which patients will have the potential to benefit most from our immunotherapies."

According to the companies, the TruSight Oncology 500 assay is being developed to detect most of the known biomarkers for oncology therapeutics, including tumour mutation burden and microsatellite instability for immunotherapies. Financial terms of the deal were not disclosed.

Did you like this article?